To assess whether combined therapy potentiates the ability of DCs to prime CD8+ T cells ex vivo, we incubated DCs from tumour-draining LNs with OVA-specific OT-I T cells 20 days after tumour inoculation and analysed T cell activation by evaluating IFN-γ production. Here, CD8A is linked to neoplasm.